Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC extends comment period

This article was originally published in The Tan Sheet

Executive Summary

FTC grants a 90-day extension of the March 19 deadline for comments related to the commission's Guides Concerning the Use of Endorsements and Testimonials in Advertising and two consumer surveys it commissioned. The Electronic Retailing Association said it needs more time to evaluate the two reports and compile member opinions on the subject, FTC states. The new deadline for comments is June 18, according to FTC. The commission published the results of the two commissioned studies on efficacy of testimonial ads' disclosure statements in January. The studies found dietary supplements' disclosure statements are largely ineffective in helping consumers understand efficacy claims communicated in a testimonial advertisement (1"The Tan Sheet" Jan. 22, 2007, p. 10)....

You may also be interested in...

Disclosure Statements In Testimonial Ads Largely Ineffective – FTC Studies

Results from two studies funded by the Federal Trade Commission show disclosure statements for dietary supplements are largely ineffective in helping consumers understand product efficacy claims after they view testimonial advertisements

First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands

The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.

ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Emerging Company Profile: Backed by $20m in seed funding, the UK firm is going against the grain by antagonizing, instead of agonizing, G protein-coupled receptor 35 with an eye to treating colorectal cancer and other gastrointestinal conditions.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts